- These 2 Biotechs May Surprise Investors, Says Janney Analyst Kimberly Lee
- GW Pharmaceuticals: Giving New Meaning To 'High Potential'
- Canaccord Genuity Sees Strong Upside In Venaxis' Shares And Set A $7 Price Target
- Sucampo's Stock Could Reach $12, Says Maxim's Senior Vice President
- These 4 Biotech Stocks Have Upside, Says Burrill's Senior Analyst
Ben Yoffe
ABOUT
Ben Yoffe is a professional biotechnology investor and writer from Israel. His goal is to highlight firms which he believes are offering compelling risk/reward opportunities. He believes in research, asking questions and often reach out to analysts and CEOs regarding the companies he covers.
SNAPSHOT
- Description: Journalist. Trading frequency: Infrequent
- Interests: Stocks - long, Tech stocks
COMPANY
BLOG
Currently, there are no blog details for Ben Yoffe.
Book
Currently, there are no book details for Ben Yoffe.
Latest Comments
more »
Latest comments on Ben Yoffe's Articles
LATEST ARTICLES & INSTAPOSTS
more »